Genentech Hillsboro Device Fill-Finish Expansion, Oregon

The Genentech Hillsboro fill-finish expansion is a $750 million plant for something the company currently brings in from overseas: the prefilled syringes and autoinjectors its drugs ship in. Oregon Gov. Tina Kotek and Genentech executives broke ground on Sept. 28, 2026, about five weeks after the August announcement.

It’s a big addition to a mature campus. Genentech opened its 75-acre Hillsboro site in 2006, and it’s now Roche’s main U.S. drug product manufacturing site, with three filling lines, packaging and a distribution center serving about a third of the Roche U.S. market. More than 800 people work there.

Project Scope

The new building covers 211,000 square feet, which Genentech says roughly doubles the site. It’ll handle device fill-finish, including combination products, with flexible high- and low-volume filling, inspection, device assembly, packaging and cold storage. Genentech says it’ll run on automation and robotics and carry a full digital twin of the factory floor for real-time monitoring.

Skanska is the general contractor, according to Construction Dive’s Oct. 2 roundup of the groundbreaking. The architect and engineers haven’t been named. For context, Flad Architects designed the campus’s original 295,000-square-foot fill-finish facility as part of a design-build team, and nobody has said whether that relationship carries over.

Construction should employ about 200 people. Commercial operations are planned for 2031, which leaves a long runway for qualification and validation after the building is up.

Why It Matters

Most U.S. pharma onshoring headlines are about drug substance plants. This one sits further down the chain. A biologic made in the U.S. still has to be filled into a device, and right now Genentech’s devices for American patients come from abroad, according to Hillsboro site leadership. Device fill-finish is specialized cleanroom work, which is why the plant won’t run commercially until 2031.

The project falls under Roche and Genentech’s $50 billion U.S. manufacturing and R&D commitment, alongside the roughly $2 billion Holly Springs, North Carolina, plant that recently topped out.

The public money isn’t settled. OPB reported in August that a forgivable loan from the Governor’s Strategic Reserve Fund was in the works, with the amount undisclosed. Genentech’s 15-year property tax abatement from the original build ended in 2025, and as of August it hadn’t applied for an Enterprise Zone exemption. Expect that conversation to come back before 2031.

Project Team & Details